Saudi Arabia Immune Checkpoint Inhibitors Market Size & Outlook
Related Markets
Saudi Arabia immune checkpoint inhibitors market highlights
- The Saudi Arabia immune checkpoint inhibitors market generated a revenue of USD 237.8 million in 2023 and is expected to reach USD 705.0 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 16.8% from 2024 to 2030.
- In terms of segment, pd-1 was the largest revenue generating type in 2023.
- Other Types is the most lucrative type segment registering the fastest growth during the forecast period.
Immune checkpoint inhibitors market data book summary
| Market revenue in 2023 | USD 237.8 million |
| Market revenue in 2030 | USD 705.0 million |
| Growth rate | 16.8% (CAGR from 2024 to 2030) |
| Largest segment | Pd-1 |
| Fastest growing segment | Other Types |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | PD-1, PD-L1, CTLA-4, Other Types |
| Key market players worldwide | Sanofi SA, Roche, Merck & Co Inc, Bristol-Myers Squibb Co, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, AstraZeneca PLC, Shanghai Junshi Biosciences Co Ltd Class H, BeiGene Ltd ADR, GlaxoSmithKline |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 0.5% of the global immune checkpoint inhibitors market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia immune checkpoint inhibitors market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 214.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immune Checkpoint Inhibitors Market Scope
Immune Checkpoint Inhibitors Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| BeiGene Ltd ADR | View profile | 10000 | c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, Cayman Islands, KY1-1108 | https://www.beigene.com |
| Shanghai Junshi Biosciences Co Ltd Class H | View profile | 2568 | Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, China, People's Republic of | https://www.junshipharma.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Regeneron Pharmaceuticals Inc | View profile | 13450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | https://www.regeneron.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
Saudi Arabia immune checkpoint inhibitors market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immune checkpoint inhibitors market will help companies and investors design strategic landscapes.
Pd-1 was the largest segment with a revenue share of 73.63% in 2023. Horizon Databook has segmented the Saudi Arabia immune checkpoint inhibitors market based on pd-1, pd-l1, ctla-4, other types covering the revenue growth of each sub-segment from 2018 to 2030.
- Saudi Arabia Immune Checkpoint Inhibitors Type Outlook (Revenue, USD Million, 2018-2030)
- PD-1
- PD-L1
- CTLA-4
- Other Types
- Saudi Arabia Immune Checkpoint Inhibitors Application Outlook (Revenue, USD Million, 2018-2030)
- Breast Cancer
- Bladder Cancer
- Colorectal Cancer
- Other Applications
- Lung Cancer
- Melanoma
- Cervical Cancer
- Hodgkin Lymphoma
- Saudi Arabia Immune Checkpoint Inhibitors Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
Reasons to subscribe to Saudi Arabia immune checkpoint inhibitors market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Saudi Arabia immune checkpoint inhibitors market databook
-
Our clientele includes a mix of immune checkpoint inhibitors market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia immune checkpoint inhibitors market, including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia immune checkpoint inhibitors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Saudi Arabia Immune Checkpoint Inhibitors Market Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
